Sapacitabine

N/A

Report date: 2024/09/30 20:00:32
NME

Base Information

Drug NameSapacitabine
Drug Alias Name沙帕他滨sapacitabinasapacitabine沙西他滨sapacitabinum +[7] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionDNA polymerase alpha subunit inhibitors
TargetsDNA polymerase alpha subunit
Therapy Area/IndicationsMyelodysplastic SyndromesCarcinoma, Non-Small-Cell LungBreast Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesSweden +[12] 
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesDaiichi Sankyo Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer Institute
Inactive CompaniesCyclacel Pharmaceuticals IncThe University Of Texas MD Anderson Cancer Center
Active IndicationsBreast Neoplasms
Inactive IndicationsMyelodysplastic SyndromesCarcinoma, Non-Small-Cell LungLymphoma, T-Cell, Cutaneous +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG